TrialDrug design, development and therapy2016

Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial.

Sachio Fushida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.